- Home
- CMS vs BMRN Comparison
CMS vs BMRN Comparison
Compare CMS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMS
- BMRN
- Stock Information
- Founded
- CMS 1987
- BMRN 1996
- Country
- CMS United States
- BMRN United States
- Employees
- CMS N/A
- BMRN N/A
- Industry
- CMS Power Generation
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CMS Utilities
- BMRN Health Care
- Exchange
- CMS Nasdaq
- BMRN Nasdaq
- Market Cap
- CMS 20.6B
- BMRN 16.1B
- IPO Year
- CMS N/A
- BMRN 1999
- Fundamental
- Price
- CMS $71.03
- BMRN $69.47
- Analyst Decision
- CMS Buy
- BMRN Buy
- Analyst Count
- CMS 15
- BMRN 19
- Target Price
- CMS $68.93
- BMRN $97.37
- AVG Volume (30 Days)
- CMS 2.0M
- BMRN 1.4M
- Earning Date
- CMS 10-31-2024
- BMRN 10-29-2024
- Dividend Yield
- CMS 2.90%
- BMRN N/A
- EPS Growth
- CMS 30.41
- BMRN 154.24
- EPS
- CMS 3.26
- BMRN 1.33
- Revenue
- CMS $7,406,000,000.00
- BMRN $2,588,398,000.00
- Revenue This Year
- CMS $5.95
- BMRN $17.93
- Revenue Next Year
- CMS $3.06
- BMRN $11.11
- P/E Ratio
- CMS $21.78
- BMRN $52.13
- Revenue Growth
- CMS N/A
- BMRN 15.83
- 52 Week Low
- CMS $52.12
- BMRN $67.75
- 52 Week High
- CMS $71.57
- BMRN $99.56
- Technical
- Relative Strength Index (RSI)
- CMS 61.34
- BMRN 34.18
- Support Level
- CMS $68.96
- BMRN $69.53
- Resistance Level
- CMS $71.32
- BMRN $70.90
- Average True Range (ATR)
- CMS 0.91
- BMRN 1.18
- MACD
- CMS -0.07
- BMRN 0.70
- Stochastic Oscillator
- CMS 79.31
- BMRN 49.14
About CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. CMS Enterprises is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.